Integrated framework reduced residual risk and monitored exposure pathways in urban cyclotron facilities.
The operation of medical cyclotrons for PET radiopharmaceutical production presents significant radiological and environmental challenges that require systematic risk assessment and evidence-based mitigation strategies. In this study, an integrated framework combining Failure Mode and Effects Analysis (FMEA) with a quantitative Defense Effectiveness Factor (DEF) approach to evaluate and reduce residual risk in a real urban cyclotron facility. High-criticality failure modes (Risk Priority Number ≥120) affecting HVAC systems, stack exhaust, and power supply were identified and validated through a Delphi expert consensus process. These modes were addressed with multi-layered defense-in-depth strategies: redundant systems (occurrence reduction, 60–80% effectiveness), real-time monitoring (detection reduction, 40–50% effectiveness), and design robustness (severity reduction, 70–85% effectiveness). The combined DEF yielded a 96–97% risk reduction. One-way sensitivity analysis confirmed the robustness of these results, with residual annual effective dose to the representative person remaining between 50–88 μSv/year (well below the IAEA 1 mSv/year public dose constraint) even under pessimistic scenarios. Primary exposure pathways were inhalation and cloud gamma from 18F and 41Ar during the early-morning production window, while secondary pathways were negligible due to the short half-lives of the radionuclides. These findings demonstrate that the integration of FMEA with DEF-based defense-in-depth and Gaussian plume modeling provides a transparent, robust, and regulatory-compliant framework for managing radioactive atmospheric emissions in urban medical cyclotron facilities.
No takes yet. Share an insight, caveat, or question.
Montero-Díaz et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: